Pulmonx Corp

NASDAQ:LUNGUnited States

Sep 9, 2024

Show headlines and story abstract

• Pulmonx Announces Presentation of Clinical Data from the AeriSeal(R) CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024, from 4:05PM ET on Monday Sep 09, 2024 by GlobeNewswire

  4:05PM ET on Monday Sep 09, 2024 by GlobeNewswire
  Companies Mentioned: LUNG

• Pulmonx Announces Presentation of Clinical Data from the AeriSeal(R) CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024, from 4:05PM ET on Monday Sep 09, 2024 by Dow Jones

  4:05PM ET on Monday Sep 09, 2024 by Dow Jones
  Companies Mentioned: LUNG
  
  This release contains forward--looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We may, in some cases, use terms such as "look forward," "confident," "promises," "predicts," "believe," "potential," "anticipates," "expects," "plans," "intends," "may," "could, " "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward--looking statements and include, without limitation, statements about Pulmonx's ability to treat a greater number of patients and deliver significant benefits to patients. Forward--looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward--looking statements are based on Pulmonx's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward--looking statements as a result of these risks and uncertainties, which include, without limitation those related to the safety, efficacy and patient and physician adoption of the company's products, the ability to fully enroll and the final results and outcomes of clinical trials and studies involving the Company's products, the ability to obtain and maintain reimbursement codes for its products, and the company's ability to procure and maintain required regulatory approvals for its products. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Pulmonx's filings with the Securities and Exchange Commission (SEC), including the Company's Quarterly Report on Form 10-Q filed with the SEC on August 2, 2024, available at www.sec.gov. Pulmonx does not undertake any obligation to update forward--looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward--looking statements contained here/in.